Emerging Markets Earnings Roundup: Pfizer And Merck (Part 5)
This article was originally published in PharmAsia News
Executive Summary
Pfizer and Merck have more than a deal on a diabetes candidate in common as both companies saw foreign exchange and patent expiries hit the bottom line in the first quarter and see emerging markets as key growth drivers this year.